Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis
Figure 2
Bufalin combined with gefitinib overcomes HGF-triggered gefitinib resistance. (a) HCC827 and PC-9 cells were treated with various concentrations of bufalin, with or without HGF (30 ng) for 72 h. (b) HCC827 and PC-9 cells were treated with various concentrations of gefitinib, with or without bufalin (20 μM) for 72 h, in the presence or absence of HGF (30 ng). Cell growth was determined by MTT assay. Error bars indicate SD.
